Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities

Published
04 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
€4.35
55.1% undervalued intrinsic discount
15 Aug
€1.95
Loading
1Y
-7.6%
7D
-2.1%

Author's Valuation

€4.3

55.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 22%

Shared on24 Apr 25

AnalystConsensusTarget has increased revenue growth from 5.8% to 52.7% and decreased future PE multiple from 147.8x to 49.2x.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 15%

AnalystConsensusTarget has decreased revenue growth from 52.6% to 5.8%, increased profit margin from 15.6% to 17.6%, increased future PE multiple from 68.3x to 147.6x and decreased shares outstanding growth rate from 0.1% to 0.0%.